sr141716 has been researched along with haloperidol in 17 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (35.29) | 29.6817 |
2010's | 9 (52.94) | 24.3611 |
2020's | 2 (11.76) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR | 1 |
Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR | 1 |
Itkin, M; Kabir, M; Mathé, EA; Nguyễn, ÐT; Padilha, EC; Shah, P; Shinn, P; Siramshetty, V; Wang, AQ; Williams, J; Xu, X; Yu, KR; Zhao, T | 1 |
Croft, DL; Hamamoto, DT; Kehl, LJ; Norsted, BD; Simone, DA; Wacnik, PW; Wilcox, GL | 1 |
Arvanitis, L; Bauer, D; Meltzer, HY; Rein, W | 1 |
Borrelli, F; Capasso, F; Capasso, R; Izzo, AA; Mascolo, N | 1 |
Egashira, N; Fujiwara, M; Iwasaki, K; Mishima, K; Mizuki, A; Nagai, H; Nishimura, R; Ogata, A; Sano, K; Shoyama, Y | 1 |
Burston, JJ; Howard, DR; Kendler, SH; Selley, DE; Sim-Selley, LJ; Wiley, JL | 1 |
Casti, P; Casu, G; Marchese, G; Pani, L; Ruiu, S; Sanna, A; Spada, GP | 1 |
Carroll, FI; McMahon, LR; Schulze, DR | 1 |
Ashton, JC; Jain, S; Mandhane, S; Nayak, P; Rajamannar, T; Soni, D | 1 |
Busanello, A; de Freitas, CM; de Moraes Reis, E; Fachinetto, R; Ferreira, J; Figueira, FH; Leal, CQ; Mello, CF; Röpke, J; Villarinho, JG | 1 |
Boomhower, SR; Rasmussen, EB | 1 |
1 review(s) available for sr141716 and haloperidol
Article | Year |
---|---|
Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
Topics: Administration, Oral; Animals; Betamethasone; Biological Availability; Caco-2 Cells; Cell Membrane Permeability; Cells, Cultured; Dexamethasone; Dogs; Dose-Response Relationship, Drug; Humans; Hydrogen-Ion Concentration; Madin Darby Canine Kidney Cells; Mice; Molecular Structure; Neural Networks, Computer; Ranitidine; Rats; Structure-Activity Relationship; Verapamil | 2022 |
1 trial(s) available for sr141716 and haloperidol
Article | Year |
---|---|
Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cannabinoids; Double-Blind Method; Drugs, Investigational; Female; Haloperidol; Humans; Male; Middle Aged; Neurotensin; Peptide Fragments; Piperidines; Placebos; Psychotic Disorders; Pyrazoles; Pyrrolidonecarboxylic Acid; Receptors, Neurokinin-3; Research Design; Rimonabant; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome | 2004 |
15 other study(ies) available for sr141716 and haloperidol
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Highly predictive and interpretable models for PAMPA permeability.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine | 2017 |
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States | 2020 |
A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain.
Topics: Animals; Benzoxazines; Calcium Channel Blockers; Camphanes; Cannabinoids; Carrageenan; Catalepsy; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Fibrosarcoma; Haloperidol; Hand Strength; Humerus; Hyperalgesia; Male; Mice; Mice, Inbred C3H; Morpholines; Myositis; Naphthalenes; Neoplasm Transplantation; Neoplasms; Pain; Piperidines; Psychomotor Performance; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant | 2003 |
Inhibitory effect of the antidepressant St. John's wort (hypericum perforatum) on rat bladder contractility in vitro.
Topics: Acetylcholine; Adenosine Triphosphate; Animals; Anthracenes; Antidepressive Agents; Atropine; Bridged Bicyclo Compounds; Capsaicin; Depression; Electric Stimulation; Female; Haloperidol; Hypericum; Kaempferols; Male; Methysergide; Muscle Contraction; Muscle, Smooth; Naloxone; Perylene; Phentolamine; Phloroglucinol; Piperidines; Plant Extracts; Propranolol; Pyrazoles; Quercetin; Rats; Rats, Wistar; Rimonabant; Rutin; Terpenes; Tetrodotoxin; Urinary Bladder; Urinary Incontinence; Verapamil | 2004 |
Antipsychotics improve Delta9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Dopamine; Dronabinol; Haloperidol; Inhibition, Psychological; Male; Mice; Nucleus Accumbens; Piperidines; Prefrontal Cortex; Pyrazoles; Reflex, Startle; Rimonabant; Risperidone; Rotarod Performance Test | 2006 |
Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivo pharmacology in rats.
Topics: Aging; Animals; Antipsychotic Agents; Cells, Cultured; CHO Cells; Clozapine; Cricetinae; Cricetulus; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Dronabinol; Female; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Haloperidol; Male; Piperidines; Pyrazoles; Rats; Rats, Long-Evans; Receptor, Cannabinoid, CB1; Rimonabant; Sex Characteristics; Signal Transduction | 2008 |
Delta-9-tetrahydrocannabinol differently affects striatal c-Fos expression following haloperidol or clozapine administration.
Topics: Animals; Antipsychotic Agents; Blotting, Western; Clozapine; Dronabinol; Gene Expression; Genes, fos; Haloperidol; Immunohistochemistry; Male; Neostriatum; Neurons; Piperidines; Psychotropic Drugs; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant | 2008 |
Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys.
Topics: Amphetamine; Animals; Cocaine; Discrimination Learning; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Dronabinol; Female; Haloperidol; Imipramine; Macaca mulatta; Male; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Tropanes | 2012 |
Induction of glucose intolerance by acute administration of rimonabant.
Topics: Administration, Oral; Animals; Benzoxazines; Blood Glucose; Dopamine Antagonists; Eating; Fenclonine; Glucose; Glucose Intolerance; Haloperidol; Hepatocytes; Infusions, Intraventricular; Insulin; Male; Mice; Morpholines; Naphthalenes; Ondansetron; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptors, Dopamine; Receptors, Serotonin; Rimonabant; Serotonin Antagonists | 2012 |
Anandamide attenuates haloperidol-induced vacuous chewing movements in rats.
Topics: Animals; Antipsychotic Agents; Arachidonic Acids; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Endocannabinoids; Haloperidol; Male; Mastication; Movement; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Treatment Outcome | 2014 |
Haloperidol and rimonabant increase delay discounting in rats fed high-fat and standard-chow diets.
Topics: Analysis of Variance; Animals; Area Under Curve; Cannabinoid Receptor Antagonists; Choice Behavior; Conditioning, Operant; Delay Discounting; Diet, High-Fat; Dopamine Antagonists; Dose-Response Relationship, Drug; Haloperidol; Male; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Reinforcement, Psychology; Rimonabant | 2014 |